CHM.AX is trading approximately 7% down at $0.06 today, extending its recent volatility despite a lack of new company-specific catalysts.
- No fresh regulatory updates, broker actions, or company announcements were released on June 25, 2026, to explain the price move.
- The decline appears driven by general risk-off pressure toward speculative, loss-making biotech micro-caps rather than any identified internal developments at Chimeric.